Daihan Scientific대한과학
131220 · KOSDAQ · ₩131220 · 대한과학
₩3,735▲ ₩105 (2.89%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩81B | ₩72B | ₩74B | ₩72B | ₩66B |
| Cost of sales | ₩59B | ₩52B | ₩52B | ₩51B | ₩48B |
| Gross profit | ₩22B | ₩20B | ₩22B | ₩22B | ₩18B |
| Operating income | ₩5.5B | ₩4.2B | ₩6.2B | ₩7.2B | ₩5.9B |
| Net income | ₩4.8B | ₩3.9B | ₩5.2B | ₩6.2B | ₩5B |
| Net income to shareholders | ₩3.3B | ₩2.7B | ₩3.8B | ₩4.7B | ₩3.8B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩72B | ₩68B | ₩64B | ₩59B | ₩55B |
| Current assets | ₩53B | ₩47B | ₩44B | ₩39B | ₩36B |
| Cash and equivalents | ₩5B | ₩5.4B | ₩5.7B | ₩5.1B | ₩5.7B |
| Total liabilities | ₩15B | ₩15B | ₩15B | ₩15B | ₩16B |
| Current liabilities | ₩14B | ₩14B | ₩15B | ₩12B | ₩13B |
| Borrowings | ₩170M | ₩1.5B | ₩2.5B | ₩2.6B | ₩2B |
| Total equity | ₩57B | ₩53B | ₩49B | ₩44B | ₩39B |
| Shareholders' equity | ₩45B | ₩42B | ₩39B | ₩36B | ₩33B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩5.4B | ₩4B | ₩4.8B | ₩4.5B | ₩4.1B |
| Capital spending | ₩315M | ₩440M | ₩624M | ₩3B | ₩3.2B |
| Free cash flow | ₩5.1B | ₩3.5B | ₩4.2B | ₩1.5B | ₩940M |
| Dividends paid | ₩690M | ₩697M | ₩702M | ₩647M | ₩631M |
Consolidated where available. Amounts in won.
Also known as: Daihan Scientific / 대한과학 / 131220 / KRX:131220
Source: KRX statistical information